Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data.
N3
gastric cancer
lymph node ratio
prognosis
recurrence pattern
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
03
2023
accepted:
21
09
2023
medline:
9
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
N3 gastric cancer is characterized by a fairly high lymph node metastasis burden and poor outcome despite optimal therapy. Given the limitations of TNM classification, a comprehensive evaluation tool is necessary to predict the prognosis of patients with N3 gastric cancer who underwent curative surgery. This study aims to explore the outcomes and clinicopathologic prognostic factors affecting the overall survival (OS) of patients with N3 gastric cancer after surgery. Data on patients with N3 gastric cancer who underwent (sub)total gastrectomy and regional lymph node dissection between November 2005 and September 2018 (n = 169) were analyzed by Cox regression to determine the independent prognostic factors for OS. The multivariable analysis established that gender, patient performance status, metastatic lymph node ratio (MLNR), tumor grade, and adjuvant chemotherapy are significantly associated with OS. The five-year OS of the study population was 15%. Adjuvant chemoradiotherapy was applied to 72% of the patients, which resulted in an improvement in recurrence-free survival but not OS. Recurrence occurred in 103 (75%) patients, in which the most frequent recurrence site was distant metastasis. Male gender, poor performance status, grade 3 tumor, MLNR > 0.37, and not receiving adjuvant chemotherapy are predictors of poor prognosis in N3 gastric cancer after curative resection. Considering the high recurrence rates of this group, prospective studies are needed to optimize treatment strategies.
Identifiants
pubmed: 37809035
doi: 10.2147/CMAR.S412270
pii: 412270
pmc: PMC10559796
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1085-1096Informations de copyright
© 2023 Caliskan Yildirim et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
BMC Cancer. 2019 Jan 7;19(1):21
pubmed: 30616588
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Am J Clin Oncol. 2017 Feb;40(1):35-41
pubmed: 25089533
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Oncol Res Treat. 2019;42(4):209-216
pubmed: 30870846
J Am Coll Surg. 2015 Aug;221(2):280-90
pubmed: 26141465
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer Manag Res. 2019 May 28;11:4855-4870
pubmed: 31213906
Chin J Cancer. 2016 Jul 26;35(1):69
pubmed: 27460019
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
PLoS One. 2013 Nov 07;8(11):e80082
pubmed: 24348906
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
Front Oncol. 2020 Nov 30;10:614907
pubmed: 33330111
BMC Gastroenterol. 2019 Nov 15;19(1):188
pubmed: 31729975
Ann Surg Oncol. 2022 Jan;29(1):229-239
pubmed: 34283313
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
BMC Cancer. 2019 Jan 16;19(1):80
pubmed: 30651085
Ann Surg Oncol. 2020 Oct;27(11):4235-4247
pubmed: 32424582
J Clin Oncol. 2012 Jan 20;30(3):268-73
pubmed: 22184384
Eur J Surg Oncol. 2016 Sep;42(9):1253-60
pubmed: 27017273
J Clin Oncol. 2012 Jul 1;30(19):2327-33
pubmed: 22585691
Gastric Cancer. 2004;7(4):196-201; discussion 201-203
pubmed: 15616767
Cancer Commun (Lond). 2018 May 15;38(1):23
pubmed: 29764518
J Gastrointest Surg. 2016 Sep;20(9):1565-71
pubmed: 27353383
Ann Oncol. 2021 Mar;32(3):368-374
pubmed: 33278599
Lancet Oncol. 2014 Nov;15(12):1389-96
pubmed: 25439693